Program Goals. The Clinical Impact of Second-Generation Antihormonal Therapy in the Treatment of mCRPC.

Slides:

Advertisements

Similar presentations

ASCO G.U Lawrence H. Einhorn.

Advertisements

Castrate-resistant prostate cancer (CRPC)

Natural History of Prostate Cancer Local therapy Androgen deprivation therapy (ADT) Therapies after ADT Death ADT mCRPC post- docetaxel mCRPC symptomatic.

Advances in the Management of Skeletal Related Events/Bone Metastases in Prostate Cancer Robert Dreicer, M.D., M.S., FACP, FASCO Chair Dept of Solid Tumor.

Intermediate Atypical Carcinoma: Novel Histologic Subtype of mCRPC in Patients Resistant to Androgen Receptor Agonists CCO Independent Conference Highlights.

Triple-Negative and BRCA-Mutated Metastatic Breast Cancer

Updates in Prostate Cancer Prepared for GP master class – Sept 2016

Finding the Right Fit: Personalizing Treatment in Metastatic Castration-Resistant Prostate Cancer.

The Nurse View: Management of Pancreatic Cancer

New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.

Novel Regimens and Considerations in Radionuclide Therapy for mCRPC

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Evolving Paradigms in Recurrent/Metastatic SCCHN

Metastatic HER2+ Breast Cancer: Resistance

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Updates and Insights on the Medical Science of Prostate Cancer

An Introduction to DNA Damage Repair in Cancer: Beyond PARP

Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer

NOACs In Long-term VTE Treatment: A State Of The Art Review

The Challenge of Bone-Metastatic PC

New Horizons in the Management of Advanced Breast Cancer

The Clinical Enigma of Cardiogenic Shock

BRCA, HRR Deficiency, and PARP Inhibitors

Progression After Cancer Immunotherapy in Advanced NSCLC

Overall Program Goals. Overall Program Goals Current Approaches.

RAI-Refractory Thyroid Cancer: Optimizing Treatment With Multikinase Inhibitors.

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Cancer Stem Cell Therapies in Gastrointestinal Cancers

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

A patient’s view on mCRPC What to tell our fellow patients!

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

PARP Inhibitors and Cancer: What Do You Need to Know?

For the Urologist by the Urologist: Essential Concepts in Managing mCRPC.

Chronic Idiopathic Urticaria

Moving Prostate Cancer Care Forward: Putting Lessons From New Orleans and Chicago Into Practice.

Individualizing Care in Ovarian Cancer

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Advances in the Management of Severe and Life-Threatening Chemotoxicity.

Opportunities and Challenges in the Management of Advanced STS

Gene Therapy: Past, Present, and Future

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Understanding Comparative Effectiveness Data in Psoriatic Arthritis

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Immunotherapy for cSCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Personalizing Management in the Care of Patients With Advanced Sarcoma

The Evolving Treatment Landscape in Atopic Dermatitis

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Maintenance Therapy in Advanced Ovarian Cancer

What's New in Therapeutic Options for Moderate to Severe RA?

The Road to Quality Improvement in HER2-Positive Breast Cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Treatment-Resistant Schizophrenia

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Are We Making Progress in the Management of Huntington Disease?

PROSTATE CANCER CIRCULATING BIOMARKER CONSENSUS STATEMENT QUESTIONS

Program Goal. Program Goal Disclaimer Overview.

Targeting the Androgen Pathway: Current Best Practice and Future Directions.

Nat. Rev. Urol. doi: /nrurol

European Urology Oncology

Evaluating Success of Current Treatments for HCM

Overview of sample and patient characteristics for 444 tumors from 429 patients with mCRPC. Overview of sample and patient characteristics for 444 tumors.

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Evaluating the Totality of Evidence

Treatment Advances for RA

Possible outcomes of therapeutic treatments using the spiral model.

Uncovering the Right Sequence

Presentation transcript:

The Clinical Impact of Second-Generation Antihormonal Therapy in the Treatment of mCRPC

Program Goals

Discussion Overview

Overall Landscape Today: Still Rapidly Evolving

Where Are We in 2015?

Docetaxel in Hormone Treatment-Naive Disease

The Expanding Role of Abiraterone and Enzalutamide

How to Choose Between Abiraterone and Enzalutamide?

St Gallen Advanced Prostate Cancer Consensus Conference (APCCC 2015)

A Major Metabolite of Abiraterone in Humans Is a Potent AR Antagonist

Other Clinical Considerations for Abiraterone and Enzalutamide

Steroid Switch Results in Durable Responses

Other Therapeutic Options for mCRPC

Local Recurrence Symptoms Becoming an Increasing Problem

State of the Art Treatment for mCRPC: Recommendations

Clinical Genomics of Advanced Prostate Cancer: AR Pathway Aberrations

PI3K Pathway Aberrations in mCRPC

What Is the Meaning of All of This? CRPC Remains AR-Driven

What About PI3K/AKT Signaling? We May Also Need to Block AKT

DNA Repair Aberrations

Olaparib in mCRPC: Phase 2 TOPARP Trial

Olaparib in mCRPC: Results

Conclusions

Abbreviations

Abbreviations (cont)